KIKazuto Ito

Kazuto Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuto Ito has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuhiro Suzuki

    Gunma University Graduate School of Medicine

    7 shared publications
  • Hidetoshi Yamanaka

    Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan

    6 shared publications
  • Takumi Yamamoto

    Department of Urology, Gunma University School of Medicine, Maebashi, Japan

    6 shared publications
  • Masaru Ohi

    Department of Urology, Gunma University School of Medicine, Maebashi, Japan

    5 shared publications
  • Kohei Kurokawa

    From the Department of Urology, Gunma University School of Medicine, Maebashi, Japan

    4 shared publications
  • Hiroyuki Takechi

    Department of Urology, Gunma University School of Medicine, Maebashi, Japan

    3 shared publications

Latest Publications

  • Open Access

    Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan

    by Masanori Hirono, Mikio Kobayashi, Tomoyasu Tsushima, Wataru Obara, Nobuo Shinohara, Keiichi Ito, Masatoshi Eto, Tatsuya Takayama, Yasuhisa Fujii, Masaharu Nishikido, et al.

    Background: Although the percentage of patients with renal cell carcinoma (RCC) extending into venous systems is unexpectedly high, the prognostic impact and independency of venous tumor thrombus-related factors on overall survival (OS) remain controversial. Furthermore, the prognostic impact of various clinicopathologic factors including tumor thrombus-related factors on OS may change with elapsed years after the intervention and also with follow-up duration of participants. The aim of the study is to explore independent and universal predictive preoperative and intraoperative clinicopathologic factors on OS in patients with RCC extending into venous systems using subgroup analysis in terms of restricted follow-up duration and yearly-based survivors. Methods: Between 1980 and 2009, 292 patients diagnosed with RCC with venous tumor thrombus were retrospectively registered for this study. The prognostic impacts of various clinicopathologic and surgical treatment factors including levels of venous thrombus, venous wall invasion status and likelihood of aggressive cytoreductive operation, were investigated using Kaplan-Meier method and following multivariate Cox proportional hazards model for all patients and those still alive at 1, 2, and 3 years of follow-up. To investigate the impact of follow-up duration on the statistical analyses, multivariate logistic regression analyses were used to explore prognostic factors using restricted data until 1, 2, and 3 years of follow-up. Results: The median follow-up duration was 40.4 months. The 5-year OS was 47.6%. Several independent predictive factors were identified in each subgroup analysis in terms of yearly-based survival and restricted follow-up duration. The presence of tumor thrombus invading to venous wall was independently related to OS in the full-range follow-up data and in survivors at 2 and 3 years of follow-up. Using restricted follow-up data until 1, 2, and 3 years of follow-up, many independent predictive factors changed with follow-up duration, but surgical category could be universal and independent predictive factors. Conclusion: The most universal factors affecting improvement both in short-term and long-term survivals could be cytoreductive surgery and absence of venous wall invasion. It may mean that feasible aggressive cytoreductive operation following more reliable preoperative imaging for predicting venous wall invasion status would improve OS for patients with RCC extending into venous systems.


  • Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range

    by Kazuto Ito, Mai Miyakubo, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Yasuhiro Shibata, Kazuhiro Suzuki

    One of the most important issues to address when developing an optimal screening system for prostate cancer is investigating appropriate biopsy indications following serum prostate-specific antigen (PSA) measurements in order to maintain high sensitivity and avoid unnecessary biopsy.


  • Open Access

    Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme

    by M Nomura, K Ito, M Miyakubo, Y Sekine, Y Tamura, N Shimizu, S Aoki, K Suzuki

    We previously reported the diagnostic efficacy of the age- and prostate volume-adjusted prostate biopsy method (the adjusted biopsy method). Here, we developed a new nomogram for predicting cancer probability at initial biopsy using the adjusted method. Between 2002 and 2010, 1059 Japanese men with PSA levels between 1.1 and 40 ng ml−1 and biopsied for the first time using the adjusted method at Gunma University Hospital were enrolled. All subjects underwent digital rectal examination (DRE) and transrectal ultrasonography (TRUS). Data from the initial 849 subjects were used for development of the nomogram and those from the final 210 subjects were used for internal validation. External validation was conducted using data from two affiliated hospitals where the same adjusted biopsy method was used. The nomogram was developed through logistic regression analysis, and predictive accuracy and performance characteristics were assessed using the area under the curve (AUC) of the receiver operating characteristics and calibration plots. Furthermore, we compared the predictive accuracy of the newly developed nomogram with the ‘Prostate Risk Indicator’ using the development data set, as well as the two external data sets. The AUC of the logistic regression-based nomogram was significantly higher than those of any single clinical parameter. External validation showed significant correlations with the present model. The AUC-receiver operating characteristic of the ‘Prostate Risk Indicator’ was the second largest following the new nomogram using the development data set and one external data set and almost equal to the new nomogram using the other external data set. Nevertheless the present model does not include somewhat subjective findings on TRUS abnormality, which is necessary for the estimation by ‘Prostate Risk Indicator’, the predictive accuracy of the present simple nomogram could be excellent enough to contribute to accurate shared decision-making between doctors and men who are candidates for the adjusted biopsy scheme.


  • Open Access

    Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy

    by S Miyamoto, K Ito, M Miyakubo, R Suzuki, T Yamamoto, K Suzuki, H Yamanaka

    In the era when various treatment agents for advanced-stage prostate cancer are available, it is important to investigate overall survival for metastatic prostate cancer treated with step-up hormonal treatment as a reference against new treatment regimens, including antitumor agents and/or new hormonal derivatives, and it is desirable to explore pretreatment, biopsy-related and post-treatment prognostic factors to establish tailor-made treatment strategies. Between 1992 and 2002, 94 patients were diagnosed with prostate cancer with distant metastases in our facility. Various pretreatment clinical findings including serum PSA, testosterone, alkaline phosphatase (ALP), digital rectal examination (DRE) and extension of disease score were investigated for predicting outcomes in step-up hormonal treatment. We also investigated the impact of pathological findings including Gleason grading, tumor volume indices, various Gleason grade 5 volume indices in biopsy specimens, and post-treatment PSA nadir following step-up hormonal treatment on overall survival. The 3- and 5-year overall survival was 72.4% and 62.5%, respectively. According to univariate analyses, patients with PSA 100 ng ml–1, ALP –1, T1c to T3 on DRE, extension of disease (EOD) score 0–3, no Gleason grade 5 cancer in biopsy specimens or less such cancer and good response at any stage of hormonal therapy had significantly better overall survival than did patients with alternative status. A multivariate Cox proportional hazard model revealed that PSA nadir after first-line hormonal treatment, PSA nadir after second-line treatment and Gleason grade 5 volume index were independent prognostic factors. Even in very advanced prostate cancer, local pathological indices, a Gleason grade 5 volume index in particular, could differentiate patients with better prognosis from worse prognosis. Step-up hormonal therapy including luteinizing hormone-releasing hormone agonist, estrogen derivatives and steroid hormones may be valuable in patients with metastatic prostate cancer, especially in good responders at any stage of hormonal therapy.


  • Open Access

    Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells

    by Rizky Abdulah, Ahmad Faried, Kenji Kobayashi, Chiho Yamazaki, Eka W Suradji, Kazuto Ito, Kazuhiro Suzuki, Masami Murakami, Hiroyuki Kuwano, Hiroshi Koyama

    Broccoli is a Brassica vegetable that is believed to possess chemopreventive properties. Selenium also shows promise as an anticancer agent. Thus, selenium enrichment of broccoli has the potential to enhance the anticancer properties of broccoli sprouts.


  • Prostate‐specific antigen‐based screening for prostate cancer: Evidence, controversies and future perspectives

    by Kazuto Ito

    The most recent epidemiological survey revealed that the mortality rate for prostate cancer in Japan has increased and has been getting very close to that in the USA, where it has decreased since 1992. The low exposure rate of prostate‐specific antigen (PSA) screening in Japan and the high exposure rate of PSA screening in the USA may result in completely deferent trends in the mortality rate of prostate cancer between the two countries. The Japanese Urological Association recommends PSA‐based screening for men at risk of prostate cancer at age 50 years or older in general and 45 years or older in men with a family history of prostate cancer within first generation relatives. The fact sheet on screening for prostate cancer should indicate the most recent reliable clinical research on screening for prostate cancer and its demerits including false‐negative and false‐positive PSA test results and prostate biopsy, overdetection and overtreatment. However, it should be explained to the public that the demerits for PSA screening will be clarified step by step during screening, and in general, men having more information on screening results (PSA level, pathological findings of biopsy specimens, clinical stage, etc.) can understand their current situation better than those having no information on screening results, including PSA levels.


  • Open Access

    Japanese Urological Association guidelines on prostate‐specific antigen‐based screening for prostate cancer and the ongoing cluster cohort study in Japan

    by Kazuto Ito, Yoshiyuki Kakehi, Seiji Naito, Akihiko Okuyama, Japanese Urological Association

    The exposure rate of screening for prostate cancer using prostate‐specific antigen (PSA) in Japan is still very low compared with that in the USA or Western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8 times higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death.


  • Lead Time of Prostate Cancer Detected in Population Based Screening for Prostate Cancer in Japan

    by Kazuto Ito, Takumi Yamamoto, Mai Miyakubo, Hiroyuki Takechi, Masaru Ohi, Yasuhiro Shibata, Kazuhiro Suzuki

    Purpose: We clarified that lead time bias in screen detected prostate cancer is important for evaluating the outcome of any individual screening system. Materials and Methods: Between 1992 and 2001, 195 and 958 prostate cancer cases with clinical T1c/T2N0M0 and T3N0M0 disease were enrolled in the current study as screen detected and outpatient clinic detected prostate cancer, respectively. Log10 prostate specific antigen velocity was calculated using log10 prostate specific antigen at diagnosis and at the most recent screening before cancer detection. Lead time in screen detected cancer was then estimated as the year when log10 prostate specific antigen in screen detected cancer would increase to the levels of log10 prostate specific antigen in outpatient clinic detected prostate cancer. Results: Median log10 prostate specific antigen was 0.87 and 1.08 ng/ml for clinical T1c/T2N0M0 disease, and 1.14 and 1.53 ng/ml for T3N0M0 disease in screen and outpatient clinic detected cancer, respectively. The 25th, 50th and 75th percentiles of log10 prostate specific antigen velocity before cancer detection in the screening population were 0.05, 0.08 and 0.14 for T1c/T2N0M0 disease, and 0.07, 0.13 and 0.21 for T3N0M0 disease, respectively. The 25th, 50th and 75th percentiles of expected lead time in screen detected cancer were 1.9, 3.3 and 5.2 years for T1c/T2N0M0 disease and 1.4, 2.2 and 4.1 years for T3N0M0 disease, respectively. Conclusions: The lead time of screen detected cancer in our screening system is not as long as previously thought. This new methodology for lead time estimation may be useful for evaluating treatment outcomes of screen detected prostate cancer in individual screening systems done in various regions worldwide.